a public good project by the
Synthesis
Company
of California

© 2026

Tatsuya Suzuki | doi.page

0 works0 citations0 h-index

Tatsuya Suzuki

Taiho Pharmaceutical (Japan)(JP)Aomori University(JP)

Publications by Year

Research Areas

SARS-CoV-2 and COVID-19 Research, Glycosylation and Glycoproteins Research, COVID-19 Clinical Research Studies, Hepatitis C virus research, Carbohydrate Chemistry and Synthesis

Most-Cited Works

→ An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies(2021)286 cited
→ Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2(2021)144 cited
→ SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response(2022)88 cited
→ Regulation of Apoptosis during Flavivirus Infection(2017)86 cited
→ Effective Production of Levulinic Acid from Biomass through Pretreatment Using Phosphoric Acid, Hydrochloric Acid, or Ionic Liquid(2014)68 cited
→ An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo(2022)64 cited

→ SARS-CoV-2 ORF6 disrupts nucleocytoplasmic trafficking to advance viral replication(2022)

61 cited

→ Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor(2018)55 cited

→ TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis(2016)49 cited

→ Activation of the Complement System by (1.RAR.3)-.BETA.-D-Glucans Having Different Degrees of Branching and Different Ultrastructures.(1992)47 cited